Onco-Hu® models are a robust immuno-oncology platform for efficacy testing of novel immunotherapies targeting T cells and myeloid cells. The platform is based on NSG™ and NSG™-SGM3 transgenic mice, dually engrafted with human CD34+ hematopoietic stem cells (HSCs) and clinically relevant PDX Live™ low passage tumors.
As a robust pre-clinical tool for assessing proof-of-concept treatment strategies and evaluating the efficacy of immunotherapeutics, the Onco-Hu® platform better recapitulates human tumor and immune-cell interactions in vivo compared to existing models, allowing more improved physiological modeling of pathways important in therapeutic intervention. In addition to robust engraftment of low-passage patient-derived xenografts (PDX), the Onco-Hu® model stably expresses diverse human immune cells, including:
Hematopoietic stem cells
Myeloid progenitor cells
CD33+ myeloid cells
Helper T cells
Revolutionizing pre-clinical research
We can run accelerated immuno-oncology studies for you.
Our In Vivo Pharmacology Services offers optimized immuno-oncology efficacy studies to test anti-tumor responses using highly characterized Onco-Hu® models expressing high PD-L1 levels. These validated platforms support robust tumor growth and respond to check-point inhibitors, such as the anti-PD-1 receptor antibody pembrolizumab, and exhibit tumor infiltration of cytotoxic T cells and reduction of tumor growth rate (Li-Chin Yao, et al. 2015).
Figures. Onco-Hu® models engrafted with PDX Live™ clinically relevant breast, lung tumors and cell lines expressing PD-L1 allow evaluating the efficacy of immunomodulators –alone or in combination therapies– to treat cancer. Triple negative breast Onco-Hu®-TM00098 responds to Keytruda. Lung cancer -Hu®-TM00302 responds to checkpoint inhibitors Keytruda and Yervoy, compared to vehicle group.